Literature DB >> 20088713

Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines.

Dae-Sun Kim1, Jae-Hwan Nam.   

Abstract

Coxsackievirus strain CVB3 is widespread in the human population and causes myocarditis or pancreatitis. However, despite its clinical impact, there is no commercially available and clinically applicable prophylactic vaccine. This study examines the characteristics of attenuated CVB3 strains developed so far and their application as live-attenuated CVB3 vaccines, and discusses problems to be overcome in the development of live-attenuated vaccines.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20088713     DOI： 10.1517/14712590903379502

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


  9 in total

Review 1.  Is a multivalent hand, foot, and mouth disease vaccine feasible?

Authors:  Michel Klein; Pele Chong
Journal:  Hum Vaccin Immunother       Date:  2015-05-26       Impact factor: 3.452

2.  A mechanism of immunoreceptor tyrosine-based activation motif (ITAM)-like sequences in the capsid protein VP2 in viral growth and pathogenesis of Coxsackievirus B3.

Authors:  Dae-Sun Kim; Jung-Hyun Park; Joo-Young Kim; Dokeun Kim; Jae-Hwan Nam
Journal:  Virus Genes       Date:  2011-10-26       Impact factor: 2.332

Review 3.  Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

4.  In vitro molecular characterization of RNA-proteins interactions during initiation of translation of a wild-type and a mutant Coxsackievirus B3 RNAs.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Mahjoub Aouni; Jawhar Gharbi
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

5.  An attenuated coxsackievirus b3 vector: a potential tool for viral tracking study and gene delivery.

Authors:  Jun Zeng; Xiao xuan Chen; Jian ping Dai; Xiang feng Zhao; Gang Xin; Yun Su; Ge fei Wang; Rui Li; Yin xia Yan; Jing hua Su; Yu xue Deng; Kang sheng Li
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

Review 6.  Therapeutic Use of Native and Recombinant Enteroviruses.

Authors:  Jani Ylä-Pelto; Lav Tripathi; Petri Susi
Journal:  Viruses       Date:  2016-02-23       Impact factor: 5.048

Review 7.  EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.

Authors:  Qunying Mao; Yiping Wang; Lianlian Bian; Miao Xu; Zhenglun Liang
Journal:  Emerg Microbes Infect       Date:  2016-07-20       Impact factor: 7.163

Review 8.  Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.

Authors:  Huitao Liu; Honglin Luo
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

9.  The antiviral effect of jiadifenoic acids C against coxsackievirus B3.

Authors:  Miao Ge; Huiqiang Wang; Guijie Zhang; Shishan Yu; Yuhuan Li
Journal:  Acta Pharm Sin B       Date:  2014-07-16       Impact factor: 11.413
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.